Evathera
A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care
Isotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu)
FDA approves Investigational New Drug (IND) that enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE), in patients with neuroendocrine tumors (NET)
New PET Radiotracer Proven Safe and Effective in Imaging Malignant Brain Tumors
Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
